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HSP90a b s t r a c t
The aryl hydrocarbon receptor is a member of the nuclear receptor superfamily that associates with
the molecular chaperone HSP90 in the cytoplasm. The activation mechanism of the AhR is not yet
fully understood. It has been proposed that after binding of ligands such as 2,3,7,8-tetrachlo-
rodibenzo-p-dioxin (TCDD), 3methylcholanthrene (3-MC), or b-naphthoﬂavone (b-NF), the AhR dis-
sociates from HSP90 and translocates to the nucleus. It has also been hypothesized that the AhR
translocates to the nucleus and forms a complex with HSP90 and other co-chaperones. There are
a few reports about the direct association or dissociation of AhR and HSP90 due to difﬁculties in
purifying AhR. We constructed and puriﬁed the PAS domain from AhR. Binding of the AhR-PAS
domain to b-NF afﬁnity resin suggested that it possesses ligand-binding afﬁnity. We demonstrated
that the AhR-PAS domain binds to HSP90 and the association is not affected by ligand binding.
The ligand 17-DMAG inhibited binding of HSP90 to GST-PAS. In an immunoprecipitation assay,
HSP90 was co-immunoprecipitated with AhR both in the presence or absence of ligand. Endogenous
AhR decreased in the cytoplasm and increased in the nucleus of HeLa cells 15 min after treatment
with ligand. These results suggested that the ligand-bound AhR is translocated to nucleus while
in complex with HSP90.
We used an in situ proximity ligation assay to conﬁrm whether AhR was translocated to the
nucleus alone or together with HSP90. HSP90 was co-localized with AhR after the nuclear transloca-
tion. It has been suggested that the ligand-bound AhR was translocated to the nucleus with HSP90.
Activated AhR acts as a transcription factor, as shown by the transcription induction of the gene
CYP1A1 8 h after treatment with b-NF.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Molecular chaperone HSP90 is an abundant and essential pro-
tein in eukaryotic cells. HSP90 regulates the physiological func-
tions of more than 300 proteins including steroid hormone
receptors in the cells [1–3]. The aryl hydrocarbon receptor (AhR)
is a member of the basic helix-loop-helix/Per-Arnt-Sim (bHLH/
PAS) family of nuclear receptors [4,5]. AhR is the ligand-dependent
transcriptional regulator that mediates the toxic effects of chemi-
cals, such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 3methyl-
cholanthrene (3-MC) or b-naphthoﬂavone (b-NF) [5]. AhR forms a
complex with the molecular chaperone HSP90, co-chaperone
p23, and the hepatitis B virus X-associated protein XAP2 in the
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nucleus and AhR forms a complex with the partner molecules of
Arnt (AhR nuclear translocator). The AhR/Arnt heterodimer binds
to the xenobiotic responsible element (XRE) in order to react with
the xenobiotic in the promoter area of the cytochrome P450 1A1
(CYP1A1), one of the xenobiotic metabolizing enzymes. TCDD
causes toxicological effects like a suppressed immune response,
impaired reproduction, and promotion of carcinogenesis [5–9].
The AhR has several functional domains. A (bHLH) motif is
involved in the DNA binding near the NH2-terminal region. The
per-Arnt-Sim homology (PAS) domain is near the COOH-terminus
of the bHLH region. The PAS domain is made from PAS-A and
PAS-B. It has been reported that HSP90 binds to the PAS B domain,
and ligand binding to the AhR protein most probably changes the
conformation of the HSP90/AhR complex to expose the nuclear
localization signal (NLS) of AhR, leading to nuclear translocation
of the complex [10]. The glutamine (Q) rich region is near the car-
boxyl-terminal of AhR [11,12].
HSP90 may control the activation of AhR [13]. It has been
reported that HSP90 is released from the ligand-bound AhR when
co-incubated with the cell extracts containing ARNT, but not the
ARNT-deﬁcient mouse hepatoma cells [14]. Puriﬁcation of AhR, is
difﬁcult and so there are few reports regarding the direct interac-
tion between HSP90 and AhR. The activation mechanism of AhR
has not yet been fully understood and it is not known whether
the ligand-bound AhR is translocated to the nucleus by itself in
complex with HSP90.
2. Results
2.1. Association between HSP90 and AhR
In the present study, we constructed the human AhR PAS
domain [15] as shown in Fig. 1A. The PAS domain contains two
subdomains, PAS A and PAS B. The GST-AhR PAS domain was
expressed in Escherichia coli and puriﬁed (Fig. 1B). We conﬁrmedFig. 1. AhR PAS domain binds to HSP90. (A) Domain structure of human AhR. bHLH,
activation binding domain, respectively. In the present study, we constructed and puriﬁe
analyzed by SDS–PAGE (9% gel). (C) Digested GST-PAS by factor Xa were separated by SD
Mock resin (Mock) or b-naphthoﬂavone (b-NF) afﬁnity resin. The bound proteins were se
(E). In panels B and D, asterisk, double asterisks, and triple asterisks indicate uncut GSTthat the puriﬁed AhR PAS domain has a ligand-binding activity
using a b-NF afﬁnity column. The puriﬁed AhR PAS domain was
digested in PAS and GST using a Factor Xa (Fig. 1C). Although no
proteins bound to mock resin, 32-kDa protein was able to bind
to b-NF afﬁnity resin (Fig. 1D). We could conﬁrm that the b-NF
binding protein was AhR PAS by immunoblotting (Fig. 1E). Thus,
the puriﬁed AhR PAS domain possesses ligand-binding ability.
We ﬁrst analyzed whether the puriﬁed proteins make a com-
plex under ligand-free conditions. The GST-AhR PAS domain or
GST only was incubated with HSP90, and then reacted with GST
resin. As shown in Fig. 2A, no HSP90 was detected in the lane of
GST alone in the presence or absence of ATP. On the other hand,
HSP90 was detected in the lane of the GST-AhR PAS domain both
in the presence or absence of ATP. ATP has no effect on the inter-
action between the GST-PAS domain and HSP90 under the
ligand-free conditions. These results suggested that the puriﬁed
proteins had a proper interaction between HSP90 and AhR in the
absence of the ligand. We investigated the inﬂuence of 17-DMAG
on the association between HSP90 and AhR. In the presence of
17-DMAG, we could detect HSP90 as very faint proteins band
(Fig. 2B). These results suggested that 17-DMAG inhibited binding
of HSP90 to GST-PAS.
Next, we elucidated whether the ligand has an effect on the
interaction between the AhR and HSP90. We performed a ligand
treatment after the AhR PAS domain and HSP90 formed a complex.
The AhR PAS domain and HSP90 were reacted as well as the above-
mentioned experiments, then ﬁnally b-NF or DMSO was added to
the complex and incubated. After incubation, the sample was
reacted with the GST resin. As shown in Fig. 3, the lane of the
GST-AhR PAS domain could detect HSP90 in the presence or
absence of ATP and b-NF. However, the lane of GST detected only
GST, while no HSP90 was detected. These results were the same
as in Fig. 1B in the absence of ligand. The ligand did not cause dis-
sociation of the AhR PAS domain from the HSP90 complex. These
results suggested that the ligand is able to bind to the AhR PAS
domain while in complex with HSP90.PAS, and TAD indicate basic helix-loop-helix, PER-ARNT-SIM, and transcriptional
d AhR-PAS including PAS-A and PAS-B (115–387). (B) Puriﬁed GST-PAS domain was
S–PAGE (9% gel). (D) The factor Xa digested AhR-PAS domains (input) were added to
parated by SDS–PAGE (9% gel) (D) or by immunoblotting using an anti-AhR antibody
-PAS domain, cut PAS domain, and cut GST, respectively.
Fig. 2. GST pull-down assay conﬁrming the interaction of HSP90 with AhR PAS
domain in the absence or presence of 17-DMAG. The puriﬁed GST, GST-PAS, and
HSP90 were incubated with GST resin in the absence (A) or presence of 50 lM 17-
DMAG (B). The elutants from the glutathione column were analyzed by SDS–PAGE
(A: 11% gel; B: 9% gel). Lanes 1–3 of gels were input from puriﬁed GST (28 kDa),
GST-AhR PAS (57 kDa), and HSP90 (90 kDa) as a control, respectively. Pull-down
assays were performed using puriﬁed GST or GST-AhR PAS domain and puriﬁed
HSP90 in the absence () or presence (+) of ATP.
Fig. 3. Inﬂuence of ligand on the complex between AhR-PAS domain and HSP90. To
perform pull-down analysis, GST or GST-AhR PAS domain andHSP90were incubated
withGST resin in the absence () or presence (+) of ATP. After incubation, 10 lM b-NF
was added as a ligand and used for pull-down assay. DMSO was used as the control.
The elutants from the glutathione resin were analyzed by SDS–PAGE (11% gel). Lanes
1, 2, and 3 indicate GST, GST-PAS, and HSP90, respectively.
Fig. 4. Inﬂuence of ligand on AhR-PAS domain and the ability of making a complex
with HSP90. The GST or GST-AhR PAS domain was incubated with glutathione resin
in the presence of 10 lM b-NF. b-NF was added to GST or GST-PAS domain before
making a complex with HSP90. After incubation, HSP90 was added in the presence
or absence of ATP. DMSO was used as the control. Lanes 1, 2, and 3, indicates GST,
GST-PAS, and HSP90, respectively. The elutants from the glutathione resin were
analyzed by SDS–PAGE (11% gel).
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alone prior to making a complex between AhR and HSP90. The
GST-AhR PAS domain alone was treated with b-NF or DMSO, then
the reaction solution was incubated with HSP90 and reacted with
the GST resin. In all the lanes of the GST-AhR PAS domain, HSP90
was detected in the presence or absence of ATP and b-NF (Fig. 4).
In contrast, the lane where GST only was applied, no HSP90 was
detected. The GST-AhR PAS domain is still able to bind to HSP90
after binding of the ligands.
These results suggested that the ligand bound AhR PAS domain
could bind to HSP90, also the ligand could bind to the complexed
form of the AhR PAS domain with HSP90, and the AhR PAS domain
did not dissociate from HSP90 under the same conditions. The
association between HSP90 and AhR was not affected by the timing
of the ligand binding.
2.2. HSP90 is co-localized with AhR after nuclear translocation
We investigated the amounts of AhR in the cytosol after treat-
ment of ligand for 0, 15, 30, 60, and 120 min. As shown in
Fig. 5A, total amounts of AhR in the cytoplasm decreased about10%, 20%, 40%, and 80% at 15, 30, 60, and 120 min, respectively.
It has been suggested that ligand-bound AhR is translocated from
cytosol to nucleus within a short time of about 30 min. To conﬁrm
the interaction between HSP90 and the AhR, we performed an
immunoprecipitation assay. HeLa cell whole-cell extracts were
then immunoprecipitated with an anti-AhR antibody followed by
immunoblotting with an anti-HSP90 or an anti-AhR antibody.
The data clearly showed that HSP90 co-immunoprecipitated with
AhR (Fig. 5B). In the presence of the ligand, the amount of co-pre-
cipitating AhR is signiﬁcantly lower than in the absence of ligand in
the cytoplasm (Fig. 5B). We investigated the amounts of AhR in the
cytosol after treatment of b-NF for 0, 15, 30, 60, 120, and 360 min.
As shown in Fig. 5C and D, total amounts of AhR in the cytoplasm
decreased about 10%, 50%, 60%, 70%, and 70% at 15, 30, 60, 120, and
360 min, respectively. On the contrary, total amounts of AhR in the
nucleus increased about 40%, 40%, and 10% at 15, 30, and 60 min,
respectively. The quantity of AhR in the nucleus decreased about
20% and 60% at 120 and 360 min, respectively. It has been
suggested that ligand-bound AhR is translocated from cytosol to
Fig. 5. Total amounts of endogenous AhR in the cytosol and nucleus of HeLa cells. (A) HeLa cells were treated with 0.05% DMSO () or 1 lM b-NF (+) for 0, 15, 30, 60, and
120 min at 37 C. The lysate was collected and centrifuged for 60 min at 105,000g, then the supernatant was collected. AhR in the cytosol were analyzed by immnoblotting
with an anti-AhR antibody or an anti- b-actin antibody (n = 4, ⁄p < 0.05). The AhR/b-actin ratio was quantiﬁed using Image J software (Drop of Wisdom). (B) HeLa cells were
treated with 0.05% DMSO () or 3 lM b-NF (+) for 30 min at 37 C. The lysate was collected and centrifuged, then the supernatant was collected. Immunoprecipitation was
performed using an anti-Ahr antibody or anti-HSP90 antibody followed by immunoblotting with an anti-HSP90 antibody or an anti-AhR antibody. In panel, the HeLa cell
lysate (left two lanes) or immunoprecipitated samples (right two lanes) were separated by SDS–PAGE followed by immnoblotting. The subunit molecular weight of HSP90
and AhR are 90 and 110 kDa, respectively. The 50- and 32-kDa protein bands were the IgG heavy- and light chain, respectively. M, molecular marker proteins. C, HeLa cells
were treated with 0.05% DMSO (–) or 1 lM b-NF (+) for 0, 15, 30, 60, 120, and 360 min at 37 C. The lysate was collected and centrifuged for 60 min at 105,000g, then the
supernatant was collected as a cytosol fraction. Or the lysate in 2.2-M sucrose solution was centrifuged for 60 min at 30,000g, then the precipitate was collected as a nuclear
fraction. AhR, HSP90 in the cytosol or nucleus were analyzed by immnoblotting with an anti-AhR antibody and anti-HSP90 antibody. The b-actin was analyzed as a cytosol
marker protein using an anti- b-actin antibody. The Histone H1.4 was analyzed as a nucleus marker protein using a Histone H1.4 antibody. The AhR/b-actin ratio in the cytosol
and the AhR/Histone H1.4 ratio in the nucleus were quantiﬁed using Image J software (Drop of Wisdom) (D).
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we could not detect signiﬁcant changes of HSP90 quantity in the
cytosol after treatment with b-NF.
To conﬁrm the interaction between HSP90 and the AhR, we
tried to detect endogenous HSP90/AhR complex in the HeLa cells.
HeLa cells were treated with 5 lM b-NF for 2 h. In the current
study, we used in situ proximity ligation assays (PLA). The PLA
technique displayed a high sensitivity in detecting the speciﬁc
HSP90/AhR-complexes in situ. As shown in Fig. 6, in situ PLA signals
were detected in the HeLa cells as red dots. The red signals were
shown in the cytoplasm, but not in the nucleus in the absence of
b-NF. On the contrary, we could detect red dots in the nucleus
and around nucleus in the presence of b-NF. It has been suggested
that HSP90 and AhR present in the cytoplasm make a complex in
the absence of a ligand. After binding of the ligand, AhR is translo-
cated into the nucleus still in association with HSP90.
2.3. b-NF-induced expression of CYP1A1
Cytochrome P450 1A1 (CYP1A1) is one of the xenobiotic metab-
olizing enzymes (XMEs) that is induced by polycyclic aromatic
hydrocarbons (PAHs). We analyzed the mRNA of CYP1A1 by RT-
PCR (Fig. 7). CYP1A1 mRNA was induced at 2 h after the addition
of b-NF. We quantiﬁed the induction rate of CYP1A1 mRNA based
on the results of Fig. 7A and B shows the CYP1A1 mRNA level. The
CYP1A1 mRNA increase was about double at 2 h and 3 times at 8 h.
Based on these results, we conﬁrmed that HSP90 is co-localized
with AhR after nuclear translocation. It has been suggested that
HSP90 and AhR present in the cytoplasm make a complex in the
absence of a ligand. After binding of the ligand, AhR is translocated
into the nucleus while maintaining the formation in an HSP90
complex.
3. Discussion
The association between AhR and HSP90 has been demonstrated
using a sucrose density gradient [16], an immunoprecipitation
assay [17], an in vitro-translated AhR [14,18], and [35S]-methionine
labeled AhR [15,19]. The inﬂuence of HSP90 inhibitor on HSP90 and
CYP1A1 protein expression has also been reported using an immu-
noblot analysis [20], and using cultured lung AD cells [21]. How-
ever, there are few reports concerning the direct interaction
between the puriﬁed AhR and HSP90, because of the difﬁculty of
expressing and purifying AhR. The detailed nuclear localization
mechanism of AhR has not yet been fully understood.Fig. 6. b-NF induced AhR and HSP90 nuclear translocation in HeLa cells. HeLa cells were
HSP90 and AhR was measured by in situ PLA using rabbit anti-AhR antibodies, mouse
signals. Blue staining indicates DAPI staining of cell nuclei. Control was stained with non
this ﬁgure legend, the reader is referred to the web version of this article.)We constructed and puriﬁed the human AhR-PAS domain as a
GST fusion protein. Although we tried to express and purify the
His-tagged AhR-PAS domain or AhR-PAS domain alone, we could
only purify the GST-AhR PAS domain. AhR is a protein that is very
unstable and hard to purify. In the present study, we conﬁrmed the
direct interaction between the AhR PAS-domain and HSP90 using
puriﬁed proteins.
We ascertained whether or not the puriﬁed AhR PAS-domain
can bind to a ligand using an afﬁnity resin. b-NF has the functional
group C@O. In the present study, we tried to make a b-NF afﬁnity
resin using various afﬁnity resins. We selected an Epoxy-activated
Sepharose 6B.
This is particularly useful for the coupling of the small molecule
ligand. The AhR PAS-domain could bind to the afﬁnity resin, but
not to the Mock resin. This means that the puriﬁed AhR PAS-
domain forms a peculiar highly advanced structure and has a
ligand-binding ability. We investigated association between GST-
PAS and HSP90. In the absence of HSP90 inhibitor, we could detect
the association. On the contrary, the interactions were almost dis-
appeared in the presence of 17-DMAG. 17-DMAG binds to N-
domain of HSP90 and resulted in the dissociation of GST-PAS. 17-
DMAG is more effective than 17-AAG. It has been shown that 17-
DMAG signiﬁcantly reduced proteins levels of AhR in human lung
cancer adenocarcinoma H1355 cells [21]. These results suggested
that 17-DMAG-induced dissociation of HSP90 may result in AhR
degradation.
We investigated the inﬂuence on the timing of the ligand bind-
ing. If the activated AhR was translocated into the nucleus alone,
the ligand bound AhR was dissociated from HSP90. Fig. 3 shows
the result of the AhR and HSP90 complex formation ﬁrst, and then
the ligand binding to the complex. On the contrary, Fig. 4 is the
result of ligand binding to AhR ﬁrst, and after that ligand bound
AhR make a complex with HSP90. These in vitro results suggested
that AhR-HSP90 complex remains intact after binding of the ligand,
and that the activated AhR may be translocated to the nucleus with
HSP90.
We also analyzed whether or not the ligand-bound AhR makes a
complex with HSP90 using in situ proximity ligation assays (PLA).
In situ PLA signals of HSP90/AhR-complexes were detected in the
HeLa cells as red dots. It has been suggested that the ligand-bound
AhR, which was translocated in a nucleus with HSP90, substitution
of HSP90 and Arnt, and activated AhR worked as a transcription
factor, and as a result, CYP1A1 was induced. Based on the in vitro
and in vivo results, we concluded that AhR and HSP90 were trans-
located into the nucleus as a complex.treated with b-NF (5 lM) or DMSO (0.1%) for 120 min. Complex formation between
anti-HSP90 antibodies, and corresponding reagents. In situ PLA is indicated by red
-immune rabbit- and mouse serum. (For interpretation of the references to color in
Fig. 7. Analysis of CYP1A1 in the 3MC treated HeLa cells using RT-PCR. (A) HeLa
cells were treated with b-NF (3 lM) or DMSO (0.1%) for 0, 2, 4, and 8 h. CYP1A1 or b-
actin was ampliﬁed using RT-PCR, then detected by agarose gel electrophoresis as
described under ‘‘Section 4’’. (B) The CYP1A1/b-actin ratio based on (A) was
quantiﬁed using Image J software. The white bars indicate DMSO control and gray
bars indicate b-NF treated cells.
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published reports, but few give details at the biochemical protein
level. We showed directly the interaction of AhR and HSP90 using
puriﬁed protein in the present study. AhR is translocated into
nucleus with HSP90. 17-DMAG induces a dissociation of HSP90
from AhR. The AhR–HSP90 complex is not affected by the timing
of ligand binding. We also showed the AhR–HSP90 complex in
nucleus after treatment with ligand by PLA.
4. Materials and methods
4.1. Materials
The rabbit polyclonal anti-HSP90 was previously described [22].
b-NF as the ligand of AhR was purchased from Sigma–AldrichJapan, and the ligand stock solution was initially dissolved in
dimethylsulfoxide (DMSO) which was purchased from Sigma–
Aldrich Japan. 17-(Dimethylaminoethylamino)-17-demethoxygel-
danamycin (17 DMAG) as the inhibitor of HSP90 was purchased
from Invitrogen (San Diego, U.S.A.). Isopropyl-1-thio-b-D-galacto-
pyranoside (IPTG) was purchased from Nakarai Tesque. 40,6-Diami-
dino-2-phenylindole, dihydrochloride (DAPI) was purchased from
Life Technologies.
The total RNA was isolated from the HeLa cells using the RNeasy
Mini Kit (Qiagen, Valencia, CA). The amount and purity of the total
RNA was estimated by spectrophotometric analysis at A260 and
A280. The RNA quality was determined by agarose gel electropho-
resis following ethidium bromide staining. Aliquots of the total
RNA were diluted in diethylpyrocarbonated (DEPC)-treated water
and stored at 80 C. RNA (4 lg) was used to synthesize the ﬁrst
strand complementary DNA (cDNA) with Super Script III First-
Strand (Invitrogen) under the following general conditions: dena-
turation at 94 C for 15 s, annealing at 55 C for 30 s, and extension
at 68 C for 30 s for up to 40 cycles using an iCycler (BioRad). The
cDNAs were PCR-ampliﬁed by iCycler (BioRad) with the primers
of AhR. The AhR-PAS domain [1326] was ampliﬁed by PCR (iCycler,
BioRad) using the forward primer 50-GTCGACATGGGAGAATTCT-
TATTACAGGCTCTGA-30 and reverse primer 50-GCGGCCGCTCATCCA
TTTTTATAAAGCAGG-3. The resulting PCR products were inserted
into the SalI/NotI sites of the pGEX-5X-3 vector (Takara Bio, Japan).
The pGEX-5X-3-AhR-PAS constructs were checked by a DNA
sequencer (PRISM 3100, ABI). A full length cDNA of HSP90a was
kindly provided by Dr. Yokoyama (RIKEN, Japan). To generate the
HSP90 recombinant protein expression, the HSP90 cDNA was
ampliﬁed by PCR (iCycler, BioRad) using the forward primers
50-GGATCCATGCCTGAGGAAACCCAGACC-30 and reverse primer
50-TCTAGATTAGTCTAGTTCTTCCATGCG-3. The resulting PCR prod-
ucts were inserted into the BamHI/XbaI sites of the pColdI vector
(Takara Bio, Japan). The generated pColdI-HSP90 constructs were
conﬁrmed by DNA sequencing (PRISM 3100, ABI).
4.2. Recombinant protein expression and puriﬁcation
The AhR PAS domain was expressed in an E. coli Arctic Express
Competent Cell (Stratagene). The cells were grown at 30 C in LB
BROTH medium (Invitrogen) supplemented with 100 lg/ml ampi-
cillin for 3 h, then cultured at 10 C for 30 min. The cells were next
induced by the addition of 0.5 mM IPTG and the cultures were
incubated at 10 C for an additional 24 h. The cells were harvested
by centrifugation at 20,000g for 15 min at 4 C, and the cell pellets
were suspended in 10 mM Tris–HCl, pH 7.4. The cells were soni-
cated, centrifuged at 20,000g for 10 min at 4 C and the formed pel-
lets collected. The collected pellets were suspended in buffer (1 M
Arginine, 10 mM Tris–HCl, pH 7.4), then dialyzed with 10 mM Tris–
HCl, pH 7.4, overnight to remove the Arginine. After dialysis, the
lysates were cleared by centrifugation at 20,000g for 10 min at
4 C. The supernatant was applied to glutathione columns (Gluta-
thione Sepharose 4B, GE Healthcare Life Science), washed with
10 mM Tris–HCl, pH 7.4, and then eluted with elution buffer
(20 mM Glutathione, 10 mM Tris–HCl, pH 7.4). The HSP90 was
expressed in E. coli BL21 (Promega). The cells were grown in LB
BROTH medium (Invitrogen) supplemented with 100 lg/ml ampi-
cillin until the OD600 reached 0.5 at 37 C. The culture medium
was cooled for 30 min to 15 C. The cells were then induced by
the addition of 0.5 mM IPTG, and the culture was incubated at
15 C for an additional 24 h. The cells were sonicated for two
cycles, centrifuged at 20,000g for 10 min at 4 C, then the superna-
tants were collected. Proteins were applied to the Q Sepharose col-
umn (GE Healthcare Life Science), then washed with wash buffer
(0.3 M NaCl in 10 mM Tris–HCl, pH 7.4,). After washing, the pro-
teins were eluted with a linear gradient of 0.3–0.6 M NaCl in
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ultraﬁltration, mixed in an equal amount of Ni column applied buf-
fer (40 mM Imidazole in 10 mM Tris–HCl, pH 7.4), and applied to
the Ni–NTA afﬁnity column (GE Healthcare Life Science) equili-
brated with the Ni column equilibration buffer (20 mM Imidazole,
300 mM NaCl in 10 mM Tris–HCl, pH 7.4). After washing with the
Ni column wash buffer (50 mM Imidazole, 300 mM NaCl in 10 mM
Tris–HCl, pH 7.4, the proteins were eluted with a linear gradient of
0.1–0.5 M imidazole in 0.3 M NaCl, 10 mM Tris–HCl, pH 7.4). The
HSP90 fractions were concentrated by ultraﬁltration. The protein
concentration was then measured using the standard BCA assay
(Thermo Scientiﬁc).
4.3. GST pull-down assay
For the GST pull-down assay, 2.5 lM GST-AhR PAS or 2.5 lM
GST protein was added to a solution of 2.5 lM HSP90, 50 lM 17-
DMAG, 1 mM ATP, and 150 ll buffer A (0.1 M KCl, 10 mM MgCl2,
20 mM Na2MoO4, 0.6 M NaCl, 5% Glycerol, 0.1% NP-40 in 25 mM
Hepes–KOH, pH 7.4). The total volume of the sample was 300 ll
by adding buffer B (5% Glycerol, 0.1% NP-40 in 25 mM Hepes–
KOH pH 7.4) and incubated using a rotator (LD-79, Labinco) with
gentle rotation for 15 min at 37 C. The samples were loaded onto
a GST resin (GE Healthcare Life Science) equilibrated with buffer C
(50 mM KCl, 5 mM MgCl2, 10 mM Na2MoO4, 0.3 M NaCl, 5% Glyc-
erol, 0.1% NP-40 in 25 mM Hepes–KOH, pH 7.4) and incubated at
4 C for 15 min with gentle rotation followed by spinning at
2100g for 10 s at 4 C to remove the supernatant. The beads were
washed three times with buffer C and eluted by boiling at 100 C
for 5 min in SDS sample buffer. For the ligand treatment, the pro-
teins were similarly reacted with the GST resin. An aliquots of
10 lM b-NF or DMSO in 300 ll of buffer C was then added to the
sample, incubated at RT for 30 min with gentle rotation followed
by spinning at 2100g for 10 s at 4 C to remove the supernatant.
The beads were washed three times with buffer C and eluted by
boiling at 100 C for 5 min in SDS sample buffer. For the ligand
treatment before the addition of HSP90, the GST-AhR PAS or GST
protein was reacted with b-NF or DMSO and 150 ll buffer A. The
sample total was 300 ll by adding buffer B. The samples were then
incubated for 30 min at RT with gentle rotation, added to 2.5 lM
HSP90 and 1 mM ATP, and incubated for 15 min at 37 C with gen-
tle rotation. The samples were then similarly treated as previously
described. All the GST pull-down samples were separated by SDS–
PAGE (9% gel) and detected by Coomassie Brilliant Blue R-250
staining.
4.4. Afﬁnity chromatography
b-NF-Sepharose was prepared using b-NF (Sigma–Aldrich
Japan) and Epoxy-activated Sepharose 6B (GE Healthcare Life Sci-
ence) according to the manufacturer’s instructions. The puriﬁed
GST-PAS (200 lg) was digested using Factor Xa (GE Healthcare Life
Science) according to the manufacturer’s instructions. The digested
samples were added to b-NF-Sepharose or Mock (without b-NF)-
Sepharose equilibrated with 25 mM Hepes (pH 7.4) buffer and
incubated with gentle rotation using a rotator (LD-79, Labinco)
for 30 min at 4 C. After washing with the same buffer three times,
the bound proteins were separated by SDS–PAGE or by immuno-
blotting using an anti-AhR antibody.
4.5. Cell culture and transfection
The human cervical cancer cell line, HeLa cell, was maintained
in Dullbecco’s modiﬁed Eagle’s medium (DMEM; SIGMA) contain-
ing 10% fetal bovine serum (Equitech-Bio, Inc, Kerrville, TX),
20 units/ml penicillin and 20 lg/ml streptomycin (Invitrogen,Carlsbad, CA) under 5% CO2 at 37 C. Before transfection, the cul-
ture medium in the plate was replaced with DMEM containing
10% fetal bovine serum. For transfection, the expression plasmids
(pcDNA3-Flag-HA-AhR or pcDNA3) were introduced into the HeLa
cells using a FuGENE HD (Promega, Madison, WI) according to the
manufacturer’s protocol. After transfection, the cells were cultured
in DMEM before being used for analysis.
4.6. Immunoprecipitation assay
The HeLa cells were treated with 1 lM b-NF or 0.05% DMSO for
30 min at 37 C. The cells were then washed with PBS three times
and lysed in TNE buffer (Tris–HCl 10 mM pH 7.8, NaCl 0.15 M, Non-
idet P-40 1%, EDTA 1 mM, PMSF 1 mM). The lysate was collected
and centrifuged at 20,000g for 10 min at 4 C. After centrifugation,
the supernatant and precipitate were collected. The AhR antibody
(Thermo, MA1-513) were added to the supernatant or precipitate
and incubated for 2 h at 4 C. A 100 ll aliquot of Protein G Sephar-
ose (GE Healthcare Life Science) was added, then incubated for 1 h
at 4 C. The samples were washed with TNE buffer three times.
After washing, the samples were separated by SDS–PAGE or by
immunoblotting using an anti-AhR or anti-HSP90 antibody. The
precipitate of the HeLa cells, treated with 1 lM b-NF or 0.05%
DMSO for 30 min at 37 C, were separated by immunoblotting
using an anti-AhR antibody.
4.7. Subcellular fractionations of HeLa cells
The HeLa cells were treated with 1 lM b-NF or 0.05% DMSO for
30 min at 37 C. The cells were then washed with PBS three times
and lysed in TNE buffer (10 mM Tris–HCl, pH 7.8, NaCl 0.15 M,
Nonidet P-40 1%, EDTA 1 mM, PMSF 1 mM, 0.25 M sucrose). All
operations were carried out at 0–4 C. After centrifugation at
600g for 5 min, the precipitate was discarded. The 600 g superna-
tant was further centrifuged at 7000g for 10 min, and the superna-
tant (S1) and precipitate (P1) were treated by further
centrifugation. The supernatant (S1) was centrifuged at 54,000g
for 60 min, and the supernatant was further centrifuged at
105,000g for 60 min. The 105,000g supernatant was used as the
cytoplasm. Nuclear extract preparation was carried out according
to Wilson et al. [23]. The samples were separated by SDS–PAGE
or by immunoblotting using an anti-AhR or anti-HSP90 antibody.
The b-actin and Histone H1.4 were used as a cytosol and nuclear
fraction marker, respectively. The bands of AhR for 0 min express
the subcellular localization in which endogenous AhR is expressed.
Cytosol and nucleus AhR expression level are normalized against b-
actin and histone H1.4, respectively. The bar graphs indicate AhR
band level relative to the DMSO-treated control band for each
fractionation.
4.8. Cell treatment and in situ proximity ligation assay (in situ PLA)
The HeLa cells were grown on coverslips. Twenty-four hours
after culture, the cells were treated with 1 lM b-NF dissolved in
DMSO or DMSO only and incubated for 8 h. After incubation, the
cells were washed twice with cold phosphate-buffered saline
(PBS), then ﬁxed in cold methanol at 20 C for 10 min and cold
acetone at 20 C for 1 min. The ﬁxed cells were washed with
PBS twice and blocking buffer (1% BSA in PBS) for 10 min at room
temperature.
The PLA assay was performed using detection kit (Olink Biosci-
ence). HeLa cells seeded on coverslips were ﬁxed in 95% ethanol for
10 min at 37 C and incubated with 3% BSA in PBS for 1 h at room
temperature. The primary antibodies speciﬁc for AhR (anti-rabbit
AhR: Santa Cruz) and HSP90 (anti-mouse HSP90: Acris antibodies)
were added, and the slides were incubated overnight at 4 C. After
N. Tsuji et al. / FEBS Open Bio 4 (2014) 796–803 803washing threefold with TBS, the PLA Probe PLUS (anti-rabbit anti-
body) and MINUS (anti-mouse antibody), which were secondary
antibodies, were applied and the cells were stored for 2 h at
37 C. The slides were washed twice with TBS; the hybridization
solution was added for 15 min at 37 C. The slides were washed
once with TBS and incubated with ligation solution for 15 min at
37 C. After twice washing with TBS, the cells were incubated with
the ampliﬁcation solution for 90 min at 37 C and washed twice in
TBS. The detection solution was then applied for 1 h at 37 C with
shading. Finally, the cells were washed with SSC; coverslips were
mounted and visualized by confocal ﬂuorescence microscopy.
4.9. Reverse transcription-polymerase chain reaction (RT-PCR)
The total RNA was isolated from the HeLa cells treated with
DMSO or b-NF for 0, 2, 4, and 8 h using the RNeasy Mini Kit (Qia-
gen, Valencia, CA). The amount and purity of the total RNA for each
sample were estimated by spectrophotometric analysis at A260
and A280. The RNA quality was determined by agarose gel electro-
phoresis following ethidium bromide staining. Aliquots of the total
RNA were diluted in diethylpyrocarbonated (DEPC)-treated water
and stored at 80 C. RNA (4 lg) was used to synthesize the ﬁrst
strand complementary DNA (cDNA) with Super Script III First-
Strand (Invitrogen) under the following general conditions: dena-
turation at 94 C for 15 s, annealing at 55 C for 30 s, and extension
at 68 C for 30 s for up to 40 cycles using iCycler (BioRad). The
cDNAs were PCR-ampliﬁed by iCycler (BioRad) with the primers
of CYP1A1 (forward, 50-ACCACCAAGAACTGCTTAGCC-30; reverse,
50-GAAGAGTGTCGGAAG-30), b-actin (forward, 50-GCTCGTCGTCGA-
CAACGGCTC-30; reverse, 50-CAAACATGATCTGGGTCATCTTCTC-30).
The PCR products were separated in 1% agarose gels and stained
with ethidium bromide. The CYP1A1/b-actin ratio was quantiﬁed
using Image J software (Drop of Wisdom).
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